Cancer drug therapies are associated with various cardiovascular complications, among
which pulmonary hypertension (PH) has received increasing attention in recent years …

Pulmonary arterial hypertension (PAH) is a rare complication of dasatinib that was approved
as a first‐line therapy for chronic myelocytic leukemia (CML). A 24‐year‐old man presenting …

Pulmonary arterial hypertension (PAH) seems to be a rare and specific complication of
treatment with dasatinib [1]. It is diagnosed relatively late, several months after the start of …

Background: To explore a real incidence of dasatinib-induced pulmonary arterial
hypertension (D-PAH) in clinical practice, we investigated 82 imatinib or other 2G tyrosine …

In recent years, cardio-oncology has become a field of interest. Cancer drug therapies and
radiation therapy are sometimes associated with various cardiovascular complications, such …

Methods A case of pulmonary arterial hypertension (PAH) during dasatinib therapy was
retrospectively analyzed and the related literature was reviewed. Results A 55-year-old male …

Background Periodic echo-based screening to detect early stages of a rare complication of
dasatinib, pulmonary arterial hypertension (PAH), is inefficient and weakens the potential …

We read with interest the article by Weatherald et al.[1] on the long-term outcomes of
pulmonary arterial hypertension (PAH) induced by dasatinib. The authors reported 21 …

Background Pulmonary hypertension (PH) is a life-threatening disease with poor prognosis.
Encouraging efforts have been made to target the main vasoproliferative aspects of the …

Methods To present a case of pulmonary arterial hypertension (PAH) associated with long-
term exposure to dasatinib and review the related literatures. Results A 23-year-old female …